![Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation | European Respiratory Society Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation | European Respiratory Society](https://err.ersjournals.com/content/errev/22/127/66/F1.large.jpg)
Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation | European Respiratory Society
![Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator - ScienceDirect Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589004221005101-fx1.jpg)
Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator - ScienceDirect
![Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle | PNAS Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle | PNAS](https://www.pnas.org/cms/10.1073/pnas.1215982110/asset/e18ed561-41b0-4392-bfd7-e459b4db0ceb/assets/graphic/pnas.1215982110fig01.jpeg)
Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle | PNAS
![Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects | Semantic Scholar Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d2559d810755846583092108e375b02a1147ddea/2-Figure1-1.png)
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects | Semantic Scholar
![Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation - ScienceDirect Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1471489221000023-gr1.jpg)
Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation - ScienceDirect
![Cureus | A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy Cureus | A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy](https://assets.cureus.com/uploads/figure/file/227481/lightbox_715b2360cba611eba12eb94210d15e3b-Picture1-2-.png)
Cureus | A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy
![Cystic fibrosis: novel therapies, remaining challenges - Coulthard - 2018 - Journal of Pharmacy Practice and Research - Wiley Online Library Cystic fibrosis: novel therapies, remaining challenges - Coulthard - 2018 - Journal of Pharmacy Practice and Research - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/f127fbb6-46ee-440c-a4a1-10bbfabf852f/jppr1516-fig-0003-m.jpg)